Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01975818 · ClinicalTrials.gov registry record · Phase 2
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT01975818 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 201 participants.
The verdict
NCT01975818, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
Evaluate efficacy and safety of 16 weeks of titrated dose treatment with BAY85-3934 versus epoetin alfa/beta as measured by hemoglobin (Hb) levels. Fixed starting doses of 25, 50,75 and 150 mg of BAY85-3934 titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg/day
Interventions
- BIOLOGICAL Epoetin alfa/beta
- DRUG Molidustat (BAY 85-3934)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2013-10-28 |
| Est. Completion | 2015-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01975818
The ClinicalTrials.gov registry entry for NCT01975818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epoetin alfa/beta is the first listed.
NCT01975818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01975818 about?
NCT01975818 is a clinical study titled "Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934". Evaluate efficacy and safety of 16 weeks of titrated dose treatment with BAY85-3934 versus epoetin alfa/beta as measured by hemoglobin (Hb) levels. Fixed starting doses of 25, 50,75 and 150 mg of BAY85-3934 titrated at the scheduled dose control visits. Titration will be based on the subject's Hb re...
What is the current status of trial NCT01975818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2013-10-28. Estimated completion is 2015-12-15.
What interventions are being tested in trial NCT01975818?
The interventions under investigation include: Epoetin alfa/beta (BIOLOGICAL), Molidustat (BAY 85-3934) (DRUG).
Who is sponsoring clinical trial NCT01975818?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.